Adherex Technologies Inc. (TSX:AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company will be giving three poster presentations - two on its lead biotechnology compound, ADH-1, and one on its oral dihydropyrimidine dehydrogenase (DPD) inhibitor, eniluracil - at the 97th Annual Meeting of the American Association of Cancer Research in Washington, DC, April 1-5, 2006:
